Race Oncology Limited
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need… Read more
Race Oncology Limited (RAONF) - Net Assets
Latest net assets as of June 2024: $18.31 Million USD
Based on the latest financial reports, Race Oncology Limited (RAONF) has net assets worth $18.31 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.23 Million) and total liabilities ($1.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $18.31 Million |
| % of Total Assets | 90.53% |
| Annual Growth Rate | 61.58% |
| 5-Year Change | 221.83% |
| 10-Year Change | 321900.14% |
| Growth Volatility | 21477.64 |
Race Oncology Limited - Net Assets Trend (2013–2024)
This chart illustrates how Race Oncology Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Race Oncology Limited (2013–2024)
The table below shows the annual net assets of Race Oncology Limited from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $18.31 Million | -28.15% |
| 2023-06-30 | $25.49 Million | -29.42% |
| 2022-06-30 | $36.11 Million | +163.13% |
| 2021-06-30 | $13.72 Million | +141.17% |
| 2020-06-30 | $5.69 Million | +12.68% |
| 2019-06-30 | $5.05 Million | -36.32% |
| 2018-06-30 | $7.93 Million | +40.68% |
| 2017-06-30 | $5.64 Million | +38.24% |
| 2016-06-30 | $4.08 Million | +71605.57% |
| 2015-06-30 | $5.69K | +108.10% |
| 2014-06-30 | $-70.24K | -175.23% |
| 2013-06-30 | $93.38K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Race Oncology Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5740153600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $66.95 Million | 365.59% |
| Other Comprehensive Income | $8.78 Million | 47.96% |
| Other Components | $1.00 | 0.00% |
| Total Equity | $18.31 Million | 100.00% |
Race Oncology Limited Competitors by Market Cap
The table below lists competitors of Race Oncology Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Teamlease Services Limited
NSE:TEAMLEASE
|
$146.59 Million |
|
DHAWF
PINK:DHAWF
|
$146.66 Million |
|
Zhejiang Huaye Plastics Machinery Co., Ltd.
SHE:301616
|
$146.70 Million |
|
Fuzul Gayrimenkul Yatirim Ortakligi Anonim Sirketi
IS:FZLGY
|
$146.73 Million |
|
HIGHPEAK ENERGY DL-0001
F:58R
|
$146.51 Million |
|
Euroapi S.A
PINK:EAPIF
|
$146.40 Million |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC
|
$146.37 Million |
|
Harum Energy Tbk PT
JK:HRUM
|
$146.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Race Oncology Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,486,141 to 18,312,148, a change of -7,173,993 (-28.1%).
- Net loss of 13,819,000 reduced equity.
- Share repurchases of 4,621 reduced equity.
- New share issuances of 5,213,213 increased equity.
- Other comprehensive income increased equity by 1,406,568.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.82 Million | -75.46% |
| Share Repurchases | $4.62K | -0.03% |
| Share Issuances | $5.21 Million | +28.47% |
| Other Comprehensive Income | $1.41 Million | +7.68% |
| Other Changes | $29.85K | +0.16% |
| Total Change | $- | -28.15% |
Book Value vs Market Value Analysis
This analysis compares Race Oncology Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 130.65x to 10.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-06-30 | $0.01 | $1.22 | x |
| 2014-06-30 | $-0.01 | $1.22 | x |
| 2015-06-30 | $0.00 | $1.22 | x |
| 2016-06-30 | $0.08 | $1.22 | x |
| 2017-06-30 | $0.11 | $1.22 | x |
| 2018-06-30 | $0.12 | $1.22 | x |
| 2019-06-30 | $0.06 | $1.22 | x |
| 2020-06-30 | $0.05 | $1.22 | x |
| 2021-06-30 | $0.10 | $1.22 | x |
| 2022-06-30 | $0.24 | $1.22 | x |
| 2023-06-30 | $0.16 | $1.22 | x |
| 2024-06-30 | $0.11 | $1.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Race Oncology Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -345.22%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.10x
- Recent ROE (-75.46%) is above the historical average (-169.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -10.87% | 0.00% | 0.00x | 1.13x | $-19.48K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-85.35K |
| 2015 | -1534.53% | 0.00% | 0.00x | 21.89x | $-87.84K |
| 2016 | -7.80% | 0.00% | 0.00x | 1.10x | $-725.79K |
| 2017 | -74.01% | 0.00% | 0.00x | 1.06x | $-4.74 Million |
| 2018 | -79.51% | -3703.70% | 0.02x | 1.04x | $-7.10 Million |
| 2019 | -72.46% | -1601.31% | 0.04x | 1.04x | $-4.16 Million |
| 2020 | -67.59% | -2413.24% | 0.03x | 1.04x | $-4.42 Million |
| 2021 | -46.20% | -1636.61% | 0.03x | 1.04x | $-7.71 Million |
| 2022 | -31.02% | -1582.63% | 0.02x | 1.04x | $-14.81 Million |
| 2023 | -38.93% | -316.62% | 0.12x | 1.05x | $-12.47 Million |
| 2024 | -75.46% | -345.22% | 0.20x | 1.10x | $-15.65 Million |
Industry Comparison
This section compares Race Oncology Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Race Oncology Limited (RAONF) | $18.31 Million | -10.87% | 0.10x | $146.53 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |